RemeGen hopes for pain relief from expanded drug uses
The innovative drug company has so far brought only two products to market, and its high sales expenses make investors worry about fallout from an anti-corruption drive Key Takeaways: RemeGen’s…
Henlius finds elixir in first profits, scraps A-share IPO
The drug maker said last week it will halt plans for a second listing on China’s STAR Market, the same day it announced its first-ever interim profit since its 2019…
Lepu Biopharma gets taste of spring with first revenues
The ADC-focused drug company logged its first-ever sales late last year, kicking of the next phase of its development Key Takeaways: Lepu Biopharma began to sell its first product last…
Kelun-Biotech hopes for IPO booster from new Merck partnership
The company welcomed Merck as new shareholder not long after the pair signed a lucrative licensing agreement for its cutting-edge ADC cancer treatment Key Takeaways: Despite a lack of products…
InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
The Hong Kong-traded company will become the latest from the cash-challenged pharma sector to make a second listing on the A-share market Key Takeaways: InnoCare Pharma’s A-share IPO will make…
Lacking Revenue, Lepu Biopharma Chases IPO to Revive War Chest
The cutting-edge cancer treatment company has not generated any revenue from its products, and only has enough money to last another three months Key takeaways: Lepu Biopharma has yet to…
Recent Articles
RELATED ARTICLES
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK -
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
HBM gets health boost from drug licensing deals
2142.HK
-
Everest reaches new heights on growing drug sales
1952.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
